Gilead Sciences Inc (GILD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gilead Sciences Inc (GILD) has a cash flow conversion efficiency ratio of 0.147x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.33 Billion) by net assets ($22.62 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GILD net asset quality index to measure how much of total assets are equity-financed.
Gilead Sciences Inc - Cash Flow Conversion Efficiency Trend (1990–2024)
This chart illustrates how Gilead Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Gilead Sciences Inc (GILD) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Gilead Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gilead Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Novo Nordisk A/S
CO:NOVO-B
|
0.039x |
|
Marvell Technology Group Ltd
NASDAQ:MRVL
|
0.035x |
|
Industria de Diseno Textil SA
MC:ITX
|
0.178x |
|
Foxconn Industrial Internet Co Ltd
SHG:601138
|
0.052x |
|
Sumitomo Mitsui Financial Group Inc
NYSE:SMFG
|
0.471x |
|
Union Pacific Corporation
NYSE:UNP
|
0.126x |
|
AT&T Inc.
NYSE:T
|
0.059x |
|
Qualcomm Incorporated
NASDAQ:QCOM
|
0.090x |
Annual Cash Flow Conversion Efficiency for Gilead Sciences Inc (1990–2024)
The table below shows the annual cash flow conversion efficiency of Gilead Sciences Inc from 1990 to 2024. For the full company profile with market capitalisation and key ratios, see GILD stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $19.25 Billion | $10.83 Billion | 0.563x | +59.87% |
| 2023-12-31 | $22.75 Billion | $8.01 Billion | 0.352x | -17.72% |
| 2022-12-31 | $21.21 Billion | $9.07 Billion | 0.428x | -20.85% |
| 2021-12-31 | $21.06 Billion | $11.38 Billion | 0.540x | +20.56% |
| 2020-12-31 | $18.22 Billion | $8.17 Billion | 0.448x | +11.04% |
| 2019-12-31 | $22.65 Billion | $9.14 Billion | 0.404x | +3.49% |
| 2018-12-31 | $21.53 Billion | $8.40 Billion | 0.390x | -32.79% |
| 2017-12-31 | $20.50 Billion | $11.90 Billion | 0.580x | -34.08% |
| 2016-12-31 | $19.36 Billion | $17.05 Billion | 0.880x | -20.81% |
| 2015-12-31 | $19.11 Billion | $21.25 Billion | 1.112x | +37.21% |
| 2014-12-31 | $15.82 Billion | $12.82 Billion | 0.810x | +206.50% |
| 2013-12-31 | $11.74 Billion | $3.10 Billion | 0.264x | -21.03% |
| 2012-12-31 | $9.54 Billion | $3.19 Billion | 0.335x | -36.82% |
| 2011-12-31 | $6.87 Billion | $3.64 Billion | 0.530x | +14.47% |
| 2010-12-31 | $6.12 Billion | $2.83 Billion | 0.463x | -2.23% |
| 2009-12-31 | $6.51 Billion | $3.08 Billion | 0.473x | -1.35% |
| 2008-12-31 | $4.47 Billion | $2.14 Billion | 0.480x | -2.11% |
| 2007-12-31 | $3.60 Billion | $1.77 Billion | 0.490x | -24.77% |
| 2006-12-31 | $1.87 Billion | $1.22 Billion | 0.652x | +179.67% |
| 2005-12-31 | $3.03 Billion | $705.64 Million | 0.233x | -14.16% |
| 2004-12-31 | $1.87 Billion | $507.96 Million | 0.272x | +16.07% |
| 2003-12-31 | $1.00 Billion | $234.61 Million | 0.234x | +79.61% |
| 2002-12-31 | $571.34 Million | $74.41 Million | 0.130x | +146.40% |
| 2001-12-31 | $452.44 Million | $-126.98 Million | -0.281x | -157.96% |
| 2000-12-31 | $351.12 Million | $-38.20 Million | -0.109x | +48.33% |
| 1999-12-31 | $297.29 Million | $-62.60 Million | -0.211x | -36.97% |
| 1998-12-31 | $333.70 Million | $-51.30 Million | -0.154x | +10.50% |
| 1997-12-31 | $317.30 Million | $-54.50 Million | -0.172x | -203.65% |
| 1996-12-31 | $291.70 Million | $-16.50 Million | -0.057x | +62.74% |
| 1995-12-31 | $151.50 Million | $-23.00 Million | -0.152x | +52.29% |
| 1994-12-31 | $86.10 Million | $-27.40 Million | -0.318x | -63.81% |
| 1993-12-31 | $115.30 Million | $-22.40 Million | -0.194x | -204.29% |
| 1992-12-31 | $139.40 Million | $-8.90 Million | -0.064x | -82.22% |
| 1991-12-31 | $105.60 Million | $-3.70 Million | -0.035x | +85.11% |
| 1990-12-31 | $10.20 Million | $-2.40 Million | -0.235x | -- |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the t… Read more